Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Mar;42(3):664-74.
doi: 10.1097/01.ccm.0000435668.53188.80.

Serum biomarkers of brain injury to classify outcome after pediatric cardiac arrest*

Ericka L Fink  1 , Rachel P Berger, Robert S B Clark, Robert S Watson, Derek C Angus, Rudolph Richichi, Ashok Panigrahy, Clifton W Callaway, Michael J Bell, Patrick M Kochanek
Affiliations
Free PMC article
Observational Study

Serum biomarkers of brain injury to classify outcome after pediatric cardiac arrest*

Ericka L Fink et al. Crit Care Med. 2014 Mar.
Free PMC article

Abstract

Objectives: Morbidity and mortality in children with cardiac arrest largely result from neurologic injury. Serum biomarkers of brain injury can potentially measure injury to neurons (neuron-specific enolase), astrocytes (S100b), and axons (myelin basic protein). We hypothesized that serum biomarkers can be used to classify outcome from pediatric cardiac arrest.

Design: Prospective observational study.

Setting: Single tertiary pediatric hospital.

Patients: Forty-three children with cardiac arrest.

Interventions: None.

Measurements and main results: We measured serum neuron-specific enolase, S100b, and myelin basic protein on days 1-4 and 7 after cardiac arrest. We recorded demographics, details of the cardiac arrest and resuscitation, and Pediatric Cerebral Performance Category at hospital discharge and 6 months. We analyzed the association of biomarker levels at 24, 48, and 72 hours with favorable (Pediatric Cerebral Performance Category 1-3) or unfavorable (Pediatric Cerebral Performance Category 4-6) outcome and mortality. Forty-three children (49% female; mean age of 5.9 ± 6.3) were enrolled and 17 (40%) died. Serum S100b concentrations peaked earliest, followed by neuron-specific enolase and finally myelin basic protein. Serum neuron-specific enolase and S100b concentrations were increased in the unfavorable versus favorable outcome group and in subjects who died at all time points (all p < 0.05). Serum myelin basic protein at 24 and 72 hours correctly classified survival but not good versus poor outcome. Using best specificity, serum S100b and neuron-specific enolase had optimal positive and negative predictive values at 24 hours to classify both favorable versus unfavorable outcome and survival, whereas serum myelin basic protein's best accuracy occurred at 48 hours. Receiver operator curves for serum S100b and neuron-specific enolase to classify favorable versus unfavorable outcome at 6 months were superior to clinical variables.

Conclusions: Preliminary data show that serum S100b, neuron-specific enolase, and myelin basic protein may aid in outcome classification of children surviving cardiac arrest.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flowchart.
Figures 2
Figures 2
a–b. Time to peak serum NSE, S100, and MBP concentration by good vs. poor outcome and mortality at 6 months.
Figures 2
Figures 2
a–b. Time to peak serum NSE, S100, and MBP concentration by good vs. poor outcome and mortality at 6 months.
Figures 3
Figures 3
a–f. Serum NSE, S100, and MBP concentrations over the study period by good vs. poor outcome and mortality at 6 months.
Figures 3
Figures 3
a–f. Serum NSE, S100, and MBP concentrations over the study period by good vs. poor outcome and mortality at 6 months.
Figures 3
Figures 3
a–f. Serum NSE, S100, and MBP concentrations over the study period by good vs. poor outcome and mortality at 6 months.
Figures 3
Figures 3
a–f. Serum NSE, S100, and MBP concentrations over the study period by good vs. poor outcome and mortality at 6 months.
Figures 3
Figures 3
a–f. Serum NSE, S100, and MBP concentrations over the study period by good vs. poor outcome and mortality at 6 months.
Figures 3
Figures 3
a–f. Serum NSE, S100, and MBP concentrations over the study period by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
Figure 4
Figure 4
a–l. Receiver operating characteristic curves for serum and clinical variables by good vs. poor outcome and mortality at 6 months.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kuisma M, Suominen P, Korpela R. Paediatric out-of-hospital cardiac arrests--epidemiology and outcome. Resuscitation. 1995 Oct;30(2):141–150. - PubMed
    1. Reis AG, Nadkarni V, Perondi MB, Grisi S, Berg RA. A prospective investigation into the epidemiology of in-hospital pediatric cardiopulmonary resuscitation using the international Utstein reporting style. Pediatrics. 2002;109(2):200–209. - PubMed
    1. Young KD, Gausche-Hill M, McClung CD, Lewis RJ. A prospective, population-based study of the epidemiology and outcome of out-of-hospital pediatric cardiopulmonary arrest. Pediatrics. 2004 Jul;114(1):157–164. - PubMed
    1. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. JAMA. 2006 Jan 4;295(1):50–57. - PubMed
    1. de Mos N, van Litsenburg RR, McCrindle B, Bohn DJ, Parshuram CS. Pediatric in-intensive-care-unit cardiac arrest: incidence, survival, and predictive factors. Crit Care Med. 2006 Apr;34(4):1209–1215. - PubMed

Publication types

MeSH terms